Abstract
Background: Numerous artificial intelligence (AI)-enabled tools for cardiovascular diseases have been published, with a high impact on public health. However, few have been adopted into, or have meaningfully affected, routine clinical care. Objective: To evaluate current awareness, perceptions, and clinical use of AI-enabled digital health tools for patients with cardiovascular disease, and challenges to adoption. Methods: This mixed-methods study included interviews with 12 cardiologists and 8 health information technology (IT) administrators, and a follow-on survey of 90 cardiologists and 30 IT administrators. Results: We identified 5 major challenges: (1) limited knowledge, (2) insufficient usability, (3) cost constraints, (4) poor electronic health record interoperability, and (5) lack of trust. A minority of cardiologists were using AI tools; more were prepared to implement AI tools, but their sophistication level varied greatly. Conclusion: Most respondents believe in the potential of AI-enabled tools to improve care quality and efficiency, but they identified several fundamental barriers to wide-scale adoption.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 101-110 |
| Number of pages | 10 |
| Journal | Cardiovascular Digital Health Journal |
| Volume | 4 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 2023 |
Funding
This study was sponsored by Pfizer . Pfizer contributed to the study design and management and collection of data. In their role as authors, employees of Pfizer were involved in the interpretation of data; preparation, review, and approval of the manuscript; and the decision to submit for publication, along with their co-authors. The study sponsor approved the manuscript from an intellectual property perspective but had no right to veto the publication. Editorial support was provided by Donna McGuire of Engage Scientific Solutions and funded by Pfizer. The authors declare no competing nonfinancial interests but the following competing financial interests: Drs Schepart, Burton, and Bhambri are full-time employees of Pfizer and hold stock and/or stock options in Pfizer; Mr Durkin, Ms Fuller, and Ms Charap are employed by an independent research consulting firm, which was contracted by Pfizer to conduct the study; Dr F.S. Ahmad was supported by grants from the National Institutes of Health / National Heart, Lung, and Blood Institute (K23HL155970) and the American Heart Association (AHA number 856917) and has received consulting fees from Pfizer and Teladoc Livongo.
Keywords
- Artificial intelligence
- Cardiology
- Cardiovascular disease
- Digital health tool
- Electronic health records
- Machine learning
- Survey
ASJC Scopus subject areas
- Biomedical Engineering
- Critical Care and Intensive Care Medicine
- Cardiology and Cardiovascular Medicine
